ArticleJournal of fluorescence2026
Establishment of a Padlock Probe-Based Fluorescence Quantitative PCR Method for the Detection of the SARS-CoV-2 Omicron S371L Mutation.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to establish and validate a novel detection method that combines padlock probe technology with fluorescence quantitative PCR (qPCR) for the rapid and specific detection of the SARS-CoV-2 Omicron S371L mutation in the spike protein. Padlock probes and amplification primers were designed and synthesized based on the Omicron S371L mutation site. The probe was designed to anneal with high specificity to the mutation, allowing ligase-mediated circularization only in the presence of the target sequence. The circularized probe then served as a template for qPCR amplification. Assay optimization included probe concentration, ligation temperature, ligase concentration, and ligation time. Analytical sensitivity, specificity, and recovery performance were systematically evaluated. Finally, the method was validated using 30 clinical samples, with results compared to Sanger sequencing. The optimal assay conditions were identified as a padlock probe concentration of 10 nM, ligase at 0.2 U/µL, ligation carried out at 65 °C for 30 min, and 10 µL of the ligated product used for subsequent qPCR amplification. Under these parameters, the assay achieved a limit of detection of 5.78 fM and demonstrated strong linearity (R² = 0.9669). Specificity testing showed clear differentiation between the mutant template and single-, double-, or triple-base mismatches. In performance evaluations, recovery rates ranged from 89.7% to 108.0% in both PBS and urine samples. For clinical validation, the method showed complete agreement with Sanger sequencing results, yielding positive and negative predictive values of 100%. In summary, the padlock probe-based qPCR assay developed in this study offers a fast and reliable approach for detecting the Omicron S371L mutation in SARS-CoV-2. Because the method bypasses the reverse transcription step that is typically required for RNA targets, it simplifies the workflow without compromising accuracy. These features suggest that the assay could be well suited for broader clinical application, particularly in large-scale screening of emerging SARS-CoV-2 variants.
Indexed as
Identifiers
41205020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.